%PDF-1.7 % 1 0 obj <> endobj 2 0 obj <> endobj 3 0 obj <> endobj 4 0 obj <>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/Properties<>/XObject<>>>/Rotate 0/Thumb 87 0 R /TrimBox[ 36 36 630 818.64]/Type/Page>> endobj 5 0 obj [ 6 0 R 7 0 R 9 0 R 13 0 R 14 0 R 16 0 R ] endobj 6 0 obj <> endobj 7 0 obj <>/C[ 1 0.819611 0]/Contents(Based on findings from The Dapagliflozin Effect on Cardiovascular Events-Thrombosis in Myocardial Infarction 58 \(DECLARE-TIMI 58\) Trial, which showed a reduction of hospitalization for heart failure and a reduction in progression of CKD, footnote #3 within Figure 9.1 is revised to read:\n\n"Empagliflozin, canagliflozin and dapagliflzoin have shown reduction in HF and reduction in CKD progression in CVOTs"\n\nReference:\n\nWiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; for the DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-357\n\nAnnotation published March 27, 2019.\n\nAnnotation approved by PPC: March 13, 2019.\n\nSuggested citation: American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes2019 [web annotation]. Diabetes Care 2019;42\(Suppl. 1\):S90S102. Retrieved from \nhttps://hyp.is/jgq_5FCqEemiZmevyli3qw/care.diabetesjournals.org/content/42/Supplement_1/S90)/CreationDate(D:20190305085041-08'00')/F 28/M(D:20190328174520-04'00')/NM(687433df-0015-4034-b596-9cce71acf18d)/Name/Comment/P 4 0 R /Popup 6 0 R /RC(
Based on findings from The Dapagliflozin Effect on Cardiovascular Events-Thrombosis in Myocardial Infarction 58 \(DECLARE-TIMI 58\) Trial, which showed a reduction of hospitalization for heart failure and a reduction in progression of CKD, footnote #3 within Figure 9.1 is revised to read: "Empagliflozin, canagliflozin and dapagliflzoin have shown reduction in HF and reduction in CKD progression in CVOTs" Reference: Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; for the DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-357 Annotation published March 27, 2019. Annotation approved by PPC: March 13, 2019. Suggested citation: American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2019 [web annotation]. Diabetes Care 2019;42\(Suppl. 1\):S90–S102. Retrieved from https://hyp.is/jgq_5FCqEemiZmevyli3qw/care.diabetesjournals.org/content/42/Supplement_1/S90
)/Rect[ 468.181 39.5749 486.181 57.5749]/Rotate 90/Subj(Sticky Note)/Subtype/Text/T(jneumiller)/Type/Annot>> endobj 8 0 obj <>>>>>/Subtype/Form/Type/XObject>>stream HMN0.Pc=HH,KĆ Pg11 EK3l^G(^||we(E3 I9q° CäeM&ԍQhK^6%R*y=f=Mvv" &t.ϸd+њ1*Q/xaaώ_~ }V12qʷ̽`IJ`R"CB+:6Ґ :rt͠Iy xBLFs)%%Qsx;-M|+v^g!Ҡ{ė ^ endstream endobj 9 0 obj <>/C[ 1 1 0]/CreationDate(D:20190328174509-04'00')/F 4/M(D:20190328174509-04'00')/NM(e6a4cb25-b9fb-43cb-b58a-778bc0350f7d)/P 4 0 R /Popup 13 0 R /QuadPoints[ 530.063 753.081 546.004 753.081 530.063 744.872 546.004 744.872]/Rect[ 527.872 744.615 548.195 753.337]/Subj(Highlight)/Subtype/Highlight/T(HNorton)/Type/Annot>> endobj 10 0 obj <>>>/ProcSet[/PDF]/XObject<>>>/Subtype/Form/Type/XObject>>stream x2PH/ ww/Up 8 endstream endobj 11 0 obj <>/Length 17/Matrix[ 1 0 0 1 0 0]/Resources<>>>/Subtype/Form/Type/XObject>>stream xw/Up endstream endobj 12 0 obj <>/Subtype/Form/Type/XObject>>stream HD10Sp(i..^_ۍ|'(+ -^D7y %I5*ZV& oҺu{e 1!8 endstream endobj 13 0 obj <> endobj 14 0 obj <>/C[ 1 1 0]/CA 0.285004/CreationDate(D:20190328174934-04'00')/F 4/IC[ 1 1 0]/M(D:20190328175112-04'00')/NM(cc40e835-02fa-4b54-bd30-51bc4211a688)/P 4 0 R /Popup 16 0 R /RD[ 0.5 0.5 0.5 0.5]/Rect[ 469.777 49.7663 489.863 210.883]/Subj(Oval)/Subtype/Circle/T(HNorton)/Type/Annot>> endobj 15 0 obj <>>>/ProcSet[/PDF]>>/Subtype/Form/Type/XObject>>stream H\10EwN (ڥ{!YjU5}= (ȸ@~ce?P,CT